Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/R) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/R) help explain limited loss of bone mineral density over first 12 months